Unanswered Questions in HER2+ Breast Cancer
Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Approaches to Sequencing for Metastatic HER2+ BC
Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.
Clinical Implications of Tucatinib Approval in Europe
Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.
Real-World Experience With Tucatinib in Germany and France
An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.
Favorable Safety Profile of Tucatinib for Metastatic HER2+ BC
Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.
European Commission Approval of Tucatinib in HER2+ BC
Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512